This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Derick, S. Articles by Manning, M. Search for Related Content PubMed PubMed Citation Articles by Derick, S. Articles by Manning, M.

[1-Deamino-4-Cyclohexylalanine] Arginine Vasopressin: A Potent and Specific Agonist for Vasopressin V_1b Receptors

Institut National de la Santé et de la Recherche Médicale, Unité 469 (S.D., M.B.M., M.A., G.G.), 34094 Montpellier Cedex 05, France; Medical College of Ohio (L.L.C., S.S., M.M.), Department of Biochemistry and Molecular Biology, Toledo, Ohio 43614; Division d’Endocrinologie, Diabétologie et Métabolisme, Département de Médecine (M.J.V., M.G., R.C.G.), Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland; and Department of Pharmacology (N.C.W., H.H.S.), Joan and Sanford I. Weill Medical College of Cornell University, New York, New York 10021

Address all correspondence and requests for reprints to: Guillon Gilles, Institut National de la Santé et de la Recherche Médicale, Unité 469, 141 rue de la Cardonille, 34094 Montpellier Cedex 05, France. E-mail: guillon{at}u469.montp.inserm.fr.

To date, there are no vasopressin (VP) agonists that exhibit a high affinity and selectivity for the VP V_1b receptor with respect to the V_1a, V₂, and oxytocin receptors. In this study, we describe the synthesis and pharmacological properties of [1-deamino-4-cyclohexylalanine] arginine vasopressin (d[Cha⁴]AVP). Binding experiments performed on various membrane preparations revealed that d[Cha⁴]AVP exhibits a nanomolar affinity for V_1b receptors from various mammalian species (rat, bovine, human). It exhibits high V_1b/V_1a and V_1b/oxytocin selectivity for rat, human, and bovine receptors. Furthermore, it exhibits high V_1b/V₂ specificity for both bovine and human vasopressin receptors. Functional studies performed on biological models that naturally express V_1b receptors indicate that d[Cha⁴]AVP is an agonist. Like VP, it stimulated basal and corticotropin-releasing factor-stimulated ACTH secretion and basal catecholamine release from rat anterior pituitary and bovine chromaffin cells, respectively. In vivo experiments performed in rat revealed that d[Cha⁴]AVP was able to stimulate both ACTH and corticosterone secretion and exhibits negligible vasopressor activity. It retains about 30% of the antidiuretic activity of VP. This long-sought selective VP V_1b receptor ligand with nanomolar affinity will allow a better understanding of V_1b-mediated VP physiological effects and is a promising new tool for V_1b receptor structure-function studies.

This article has been cited by other articles:

				S. Dutertre, D. Croker, N. L. Daly, A. Andersson, M. Muttenthaler, N. G. Lumsden, D. J. Craik, P. F. Alewood, G. Guillon, and R. J. Lewis Conopressin-T from Conus tulipa Reveals an Antagonist Switch in Vasopressin-like Peptides J. Biol. Chem., March 14, 2008; 283(11): 7100 - 7108. [Abstract] [Full Text] [PDF]

				R. Arban V1b Receptors: New Probes for Therapy Endocrinology, September 1, 2007; 148(9): 4133 - 4135. [Full Text] [PDF]

				A. Pena, B. Murat, M. Trueba, M. A. Ventura, G. Bertrand, L. L. Cheng, S. Stoev, H. H. Szeto, N. Wo, G. Brossard, et al. Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors Endocrinology, September 1, 2007; 148(9): 4136 - 4146. [Abstract] [Full Text] [PDF]

				C. S.-L. Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon, and M. A. Ventura Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R938 - R949. [Abstract] [Full Text] [PDF]

				J. Rodrigo, A. Pena, B. Murat, M. Trueba, T. Durroux, G. Guillon, and D. Rognan Mapping the Binding Site of Arginine Vasopressin to V1a and V1b Vasopressin Receptors Mol. Endocrinol., February 1, 2007; 21(2): 512 - 523. [Abstract] [Full Text] [PDF]

				R. Ogier, E. Tribollet, P. Suarez, and M. Raggenbass Identified motoneurons involved in sexual and eliminative functions in the rat are powerfully excited by vasopressin and tachykinins. J. Neurosci., October 18, 2006; 26(42): 10717 - 10726. [Abstract] [Full Text] [PDF]

				S. Volpi, Y. Liu, and G. Aguilera Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway. J. Mol. Endocrinol., June 1, 2006; 36(3): 581 - 590. [Abstract] [Full Text] [PDF]

				J. Robert, E. Clauser, P. X. Petit, and M. A. Ventura A Novel C-terminal Motif Is Necessary for the Export of the Vasopressin V1b/V3 Receptor to the Plasma Membrane J. Biol. Chem., January 21, 2005; 280(3): 2300 - 2308. [Abstract] [Full Text] [PDF]

				S. Derick, A. Pena, T. Durroux, J. Wagnon, C. Serradeil-Le Gal, M. Hibert, D. Rognan, and G. Guillon Key Amino Acids Located within the Transmembrane Domains 5 and 7 Account for the Pharmacological Specificity of the Human V1b Vasopressin Receptor Mol. Endocrinol., November 1, 2004; 18(11): 2777 - 2789. [Abstract] [Full Text] [PDF]